ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LLOY Lloyds Banking Group Plc

53.40
-0.26 (-0.48%)
31 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lloyds Banking Group Plc LSE:LLOY London Ordinary Share GB0008706128 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.26 -0.48% 53.40 53.40 53.44 54.28 53.08 53.08 224,470,791 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Commercial Banks, Nec 23.74B 5.46B 0.0888 6.02 32.99B
Lloyds Banking Group Plc is listed in the Commercial Banks sector of the London Stock Exchange with ticker LLOY. The last closing price for Lloyds Banking was 53.66p. Over the last year, Lloyds Banking shares have traded in a share price range of 39.87p to 63.46p.

Lloyds Banking currently has 61,482,503,126 shares in issue. The market capitalisation of Lloyds Banking is £32.99 billion. Lloyds Banking has a price to earnings ratio (PE ratio) of 6.02.

Lloyds Banking Share Discussion Threads

Showing 322976 to 322997 of 437650 messages
Chat Pages: Latest  12922  12921  12920  12919  12918  12917  12916  12915  12914  12913  12912  12911  Older
DateSubjectAuthorDiscuss
03/8/2020
16:24
Brexit-Watch interview with Sammy Wilson MP on Brexit, the Withdrawal Agreement and Irish ProtocolAugust 03, 2020WELCOME to the latest in our series of interviews with people who influence Brexit. In this episode, Jonathan Saxty spoke with senior Democratic Unionist Party (DUP) politician Sammy Wilson MP. [Graphic here: linked to https://www.youtube.com/watch?v=sDeP0W8BI1U] Mr Wilson spoke about the problems with the Withdrawal Agreement, including citizens' rights, state aid rules and the Northern Irish Protocol.  The DUP chief whip asked how a 'Unionist' government can allow this to happen to Northern Ireland. Provisions in the Withdrawal Agreement rip apart the UK single market, he said, with Northern Ireland effectively taken out of the UK single market to protect the EU's so-called single market.  Mr Wilson talked about what the DUP had done and was doing to raise concerns over the Protocol; speaking about a sense of betrayal by the Conservative Government.  Mr Wilson agreed that if the Protocol goes ahead as it is currently then the prime minister will not be able to follow through on all the other promises he has made regarding Brexit.  The DUP politician explained how the Protocol can be changed and what would happen to the Protocol in the event of a no trade deal Brexit. Mr Wilson agreed that if the Protocol is not repudiated, we will not have a clean break Brexit. He described the Withdrawal Agreement as a trojan horse, allowing the EU to get behind the walls of Brexit Britain. You can view other interviews and subscribe to our brexit-watch YouTube channel here.
xxxxxy
03/8/2020
16:00
694 Alphorn, just accept that once again your efforts at petty point scoring have failed. You attempt to make the totally irrelevant point that the UK have had a number of chief Brexit negotiators and you've been put right, accept that you've been educated and move on without taking an infantile side swipe at DD's. How old are u?
utrickytrees
03/8/2020
15:47
Get out of the sun now xxxxxy!
our haven
03/8/2020
15:46
GintyPosted August 3, 2020 at 9:39 am | Permalink45k out of 67 million means that 99.99933% of our people have not died of Covid-19.For this the Tory Party destroys our economy, petrifies our people and threatens house arrest.And while we're in lockdown it makes many of our roads impassable by car and tells us we must get on our bikes – for our own good (whilst telling us to gorge ourselves silly in Pizza Hut.)
xxxxxy
03/8/2020
15:42
Lovely weather in Wales. And a great warm feeling. Brexit Glorious.Wonderful wonderful wonderful Brexit. No DealWTO
xxxxxy
03/8/2020
15:39
Still paddling in circles Pugwash? Lol
alphorn
03/8/2020
15:36
5 yrs time hopeful estimate.
Lloyds 150p a share
NWG 600p a share
(Both after some buy backs)

hamhamham1
03/8/2020
15:32
8% roughly what was lost on results day.
Am happy with a big wad of these.

hamhamham1
03/8/2020
15:29
Been out all day. Saw it was just below 26p when I went out. Looks like a 6-7% rise today if this holds.
chavitravi2
03/8/2020
15:28
Give it a year or two and then the share buy backs will start. They will reinstate the shareholder value again.
Hopefully similar to Apple, where they are going to buy back 6% of shares each year for next 3-5 years.
SP will be easy three figures medium term.

hamhamham1
03/8/2020
15:16
Barclays Capital today reaffirms its overweight investment rating on Lloyds Banking Group PLC ORD (LON:LLOY) and cut its price target to 45p (from 50p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
thomas4billing
03/8/2020
15:12
I'd say 15% divi but also 300% capital growth as well.
gaffer73
03/8/2020
15:07
People are going to look back on these prices and say "why didn't I buy when I had the chance" ?
mitchy
03/8/2020
14:59
Nah, the real money has been made by the owners of Indian and Chinese sweat shops selling masks
dope007
03/8/2020
14:52
You sycophantic slob, Alphorn. Still, I do understand your need for a friend.

Leaving that aside, the real money to be made from this tragedy will be from those pharmas making the drugs and medications necessary to treat all those who will be suffering from the effects of Covid for years to come.

poikka
03/8/2020
14:46
"ZERO CHANCE CORONOVIRUS IS NATURAL"

hxxps://www.taiwannews.com.tw/en/news/3979550

poikka
03/8/2020
14:09
Can Lloyds get a 8% bounce today?
hamhamham1
03/8/2020
14:08
max - best post today. Thank you.
alphorn
03/8/2020
14:02
From the ticker:



Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
03/08/2020 12:29pm
Dow Jones News

Johnson and Johnson (NYSE:JNJ)
Intraday Stock Chart

Monday 3 August 2020

Click Here for more Johnson and Johnson Charts.By Charley Grant
Researchers are racing to develop a Covid-19 vaccine, and investors are in a mad dash to profit from it. The financial side of this exercise is likely to run into trouble.

Promising news in the hunt for a vaccine continues to pour in. Several companies have revealed encouraging, albeit preliminary, data in clinical trials, and the U.S. government has its wallet wide open to defray research and manufacturing expenses. GlaxoSmithKline and Sanofi said Friday that the U.S. government will pay up to $2.1 billion to develop and manufacture a Covid-19 vaccine. Other companies such as Moderna and AstraZeneca have received similar contracts. These deals include the upfront purchase of hundreds of millions of doses if trials prove successful. Heavyweights Merck & Co. and Johnson & Johnson also have candidates in development.

While it won't be clear if any candidate is successful until at least the fall, investors aren't waiting around. A broad index of biotechnology stocks has surged 65% since March. Within that group, the Covid-19 vaccine makers have led the way, both large and small. The gain in market value for these companies since the spring matches the total value of some major drugmakers that generate roughly $20 billion in annual sales.

There are ample reasons for caution, despite the clearly positive news. For starters, most drug candidates in development don't reach the market. Huge research investments won't change that reality.

And, even if successful, pricing power may not be as strong as investors are hoping. The first round of doses are already paid for and priced into stocks. Pfizer and its partner BioNTech, which didn't take any government research funding, have a contract to deliver 100 million doses for a total of $1.95 billion. That comes out to about $39 per two-dose treatment.

Companies that hope to charge more than that over the long term will need to meet a very high safety and efficacy bar to make their case -- especially those that took public funds upfront. While drug pricing hasn't attracted much scrutiny this election cycle, it has been a recurring theme in American politics with major consequences for shareholders. That dynamic likely makes visions of windfall profits more dream than reality.

Granted, some risk-taking is always necessary to make money in biotech. And story stocks have a way of maintaining their upward momentum while hopes for the future are still intact -- particularly in today's euphoric investing environment.

But investors shouldn't forget that hot drug stocks can suddenly plunge even if things go according to plan. Gilead Sciences shares surged nearly 25% from March to April as anticipation built for its antiviral Covid-19 treatment remdesivir, but the stock has since lost nearly all of that ground. Those losses came despite a string of successes: The drug has been authorized for emergency use, and Gilead began selling it this summer after donating its initial supply. Last week, the company increased the midpoint of its 2020 adjusted profit guidance to $6.95 a share from $6.25.

Don't dismiss the possibility that Gilead's descent will repeat itself on a much larger, uglier scale.

Write to Charley Grant at charles.grant@wsj.com

maxk
03/8/2020
13:54
Apple $440 LOFL's
dope007
03/8/2020
13:49
Would they be down 3% today
carlcjasper
03/8/2020
13:49
G2 ...catching you up then.
alphorn
Chat Pages: Latest  12922  12921  12920  12919  12918  12917  12916  12915  12914  12913  12912  12911  Older

Your Recent History

Delayed Upgrade Clock